A Novel Strategy of ECMO Management Using Nafamostat for Regional Combined With Low Intensity Systematic Anticoagulation

Beijing Chao Yang Hospital60 enrolled

Overview

ECMO is widely used in patients with refractory respiratory and/or circulatory failure.The data shows that the incidence of bleeding and thrombotic events is still above 40%,and it is closely related to the increase in mortality rate.Therefore, optimizing ECMO anticoagulation management to reduce bleeding and thrombotic events is a key scientific issue that urgently needs to be addressed.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

Conditions

ECMO

Interventions

NafamostatDRUG

Nafamostat combined with unfractionated heparin for anticoagulation

HeparinDRUG

unfractionated heparin for anticoagulation

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * age older than 18 years old * received ECMO because of severe respiratory failure Exclusion Criteria: * anticoagulant contraindications * cerebral infarction or suspected patients * severe hypertension * women in gestational and lactational period * hemophilia * allergic to heparin or Nafamostat * unwilling or unable to complete the study

Locations (1)

Bing Sun

Beijing, Beijing Municipality, China

RECRUITING

Outcomes

Primary Outcomes

incidence of ECMO related bleeding or thrombotic events

the incidence of ECMO related bleeding or thrombotic events,such as membrane oxygenator or tube thrombotic,local blooding.

Time frame: 28 days

Central Contacts

Bing Sun, MD

CONTACT

+8613911151075 ricusunbing@126.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.